News
Zacks.com on MSN23h
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes ...
Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...
TipRanks on MSN22h
Eli Lilly’s Pediatric COVID-19 Study: A Potential Game Changer?
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is conducting a study ...
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Eli Lilly and Company is conducting a Phase 3 clinical study ...
Zacks.com on MSN22h
AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is ...
The FTSE 100 and European stocks were higher on Friday as markets turn their attention to the much-anticipated speech by US ...
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...
Although Novo Nordisk has been struggling for over a year, the relative discount may attract bullish speculators to NVO stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback